Hydrocortisone, Polymyxin B Sulfate

Verify with FDA CVM →

20 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Hydrocortisone, Polymyxin B Sulfate

Administration Routes

Auricular (Otic)UnknownTopical

Species Affected

Dog 19
Cat 1

Most Affected Breeds

Retriever - Labrador 3
Pit Bull 2
Maltese 2
Collie - Border 1
Terrier - West Highland White 1
Domestic Shorthair 1
Terrier - Boston 1
Brittany 1
Chihuahua 1
Dog (other) 1

Most Reported Reactions

Lack of efficacy - NOS 7
Emesis 5
Vomiting 3
Ear infection NOS 3
Seizure NOS 2
Appetite loss 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Diarrhoea 1
Eyes rolling back 1
Vocalisation 1
Otitis NOS 1
INEFFECTIVE, ASCARIDS NOS 1

Outcome Breakdown

Recovered/Normal
9 (45.0%)
Outcome Unknown
8 (40.0%)
Recovered with Sequela
2 (10.0%)
Ongoing
1 (5.0%)

Data Summary

Metric Value
Total adverse event reports 20
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 16
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Hydrocortisone, Polymyxin B Sulfate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 20 adverse event reports referencing Hydrocortisone, Polymyxin B Sulfate, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Hydrocortisone, Polymyxin B Sulfate. Reported administration routes include Auricular (Otic), Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Hydrocortisone, Polymyxin B Sulfate reports are Dog (19 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (3), Pit Bull (2), Maltese (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Hydrocortisone, Polymyxin B Sulfate are Lack of efficacy - NOS (7), Emesis (5), Vomiting (3), Ear infection NOS (3). Of the 20 reports with a coded outcome, Recovered/Normal is the leading category at 45.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Hydrocortisone, Polymyxin B Sulfate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial